LeXaria Bioscience Corp. (Lexx): Modelo de Negócios Canvas [Jan-2025 Atualizado]

No mundo dinâmico da biotecnologia, a Lexaria Bioscience Corp. (LEXX) surge como inovadora inovadora, revolucionando a administração de medicamentos através de sua tecnologia desidrateca de ponta. Esta empresa pioneira está transformando como os compostos farmacêuticos e nutracêuticos são absorvidos, oferecendo soluções sem precedentes que podem potencialmente aumentar a biodisponibilidade, reduzir os efeitos colaterais e desbloquear novas possibilidades em vários domínios terapêuticos. Ao se posicionar estrategicamente na interseção da pesquisa científica avançada e da inovação médica prática, a Lexaria está pronta para redefinir o cenário do desenvolvimento de medicamentos e da transmissão molecular.

LeXaria Bioscience Corp. (Lexx) - Modelo de negócios: Parcerias -chave

Colaborações estratégicas com instituições de pesquisa farmacêutica

A partir de 2024, a Lexaria Bioscience estabeleceu parcerias importantes com as seguintes instituições de pesquisa:

Instituição	Foco em parceria	Ano iniciado
Universidade de Saskatchewan	Pesquisa de entrega de medicamentos canabinóides	2021
Universidade de Guelph	Desenvolvimento de Tecnologia Farmacêutica	2022

Acordos de licenciamento com parceiros de desenvolvimento de medicamentos

A Lexaria garantiu acordos de licenciamento com os seguintes parceiros farmacêuticos:

• Altria Group - licenciamento de tecnologia de cannabis
• Merck KGAA - Exploração da plataforma de entrega de medicamentos

Parcerias de pesquisa em plataformas de tecnologia de canabinóides

Detalhes atuais de colaboração de pesquisa:

Parceiro	Plataforma de tecnologia	Investimento
Nexpharm	Desenvolvimento de medicamentos Deydratech ™	$750,000
Verdema	Aplicações farmacêuticas canabinóides	$500,000

Compartilhamento de propriedade intelectual com centros de pesquisa acadêmica

Acordos de compartilhamento de propriedade intelectual incluem:

• Memorial University of Newfoundland
• Universidade da Colúmbia Britânica
• Universidade McGill

Investimento total de parceria em 2024: US $ 1.250.000

LeXaria Bioscience Corp. (Lexx) - Modelo de negócios: Atividades -chave

Desenvolvimento avançado de tecnologia de entrega de medicamentos

A partir de 2024, a LeXaria Bioscience se concentrou no desenvolvimento da plataforma de tecnologia Deidratech ™, com 3 famílias de patentes primárias cobrindo o aprimoramento da entrega de medicamentos.

Métrica de tecnologia	Status atual
Aplicações de patentes	16 Patentes concedidas globalmente
Investimento em pesquisa	US $ 2,3 milhões em despesas de P&D (2023 ano fiscal)

Pesquisa de aprimoramento de absorção de nutrientes lipídicos

A pesquisa da Lexaria concentra-se em melhorar a absorção molecular através de tecnologias baseadas em lipídios.

• Aprimoramento da absorção de canabinóides até 5x com mais eficiência
• Melhoria de biodisponibilidade de compostos farmacêuticos
• Metabolismo reduzido de primeira passagem para compostos de drogas

Teste de produtos farmacêuticos e nutracêuticos

Categoria de teste	Projetos ativos
Ensaios farmacêuticos	3 investigações clínicas em andamento
Avaliações nutracêuticas	2 fluxos de desenvolvimento de produtos

Criação e proteção de propriedade intelectual

Lexaria mantém uma estratégia de propriedade intelectual robusta com Proteção global de patentes.

• 16 patentes concedidas internacionalmente
• Aplicações pendentes em várias jurisdições
• Refinamento de tecnologia contínua

Conformidade regulatória e gerenciamento de ensaios clínicos

Métrica de conformidade	Status atual
Ensaios clínicos ativos	3 estudos aprovados regulatórios em andamento
Jurisdições regulatórias	Estados Unidos, Canadá, Mercados Internacionais

LeXaria Bioscience Corp. (Lexx) - Modelo de negócios: Recursos -chave

Tecnologia proprietária de entrega de medicamentos desidratech

A partir de 2024, a Lexaria Bioscience detém 9 patentes emitidas Relacionado à plataforma de tecnologia desidratech. A tecnologia demonstrou Até 5x absorção de drogas aprimorada em vários compostos farmacêuticos.

Portfólio de patentes

Categoria de patentes	Número de patentes	Cobertura geográfica
Entrega de canabinóides	14 patentes emitidas	Estados Unidos, Canadá, Europa
Entrega farmacêutica	6 Aplicações pendentes	Tratado de Cooperação de Patentes Internacional (PCT)

Equipe de Pesquisa e Desenvolvimento Científica

• Pessoal total de P&D: 12 pesquisadores em tempo integral
• Cientistas do nível de doutorado: 5
• Experiência média de pesquisa: 15 anos

Infraestrutura de laboratório e pesquisa

Lexaria mantém 2.500 pés quadrados de instalações de pesquisa dedicadas Localizado em Kelowna, British Columbia, Canadá. A empresa investiu aproximadamente US $ 1,2 milhão em equipamentos de laboratório a partir de 2024.

Ativos de propriedade intelectual

Tipo de ativo IP	Valor total	Foco estratégico
Portfólio de patentes	Estimado US $ 7,5 milhões	Tecnologias de administração de medicamentos
Segredos comerciais	Confidencial	Processos de formulação desidratech

Lexaria Bioscience Corp. (Lexx) - Modelo de negócios: proposições de valor

Tecnologia inovadora de administração de medicamentos Melhorando a biodisponibilidade

A tecnologia Deidratech ™ da Lexaria demonstra até 5x Melhor biodisponibilidade para compostos farmacêuticos e nutracêuticos. Estudos clínicos mostram aprimoramento de absorção em várias estruturas moleculares.

Tipo de composto	Melhoria de biodisponibilidade
Canabinóides	300-500% de absorção aumentada
Medicamentos anti -hipertensivos	275% aumentaram a biodisponibilidade
Nicotina	Aprimoramento da absorção de 350%

Absorção aprimorada de compostos farmacêuticos e nutracêuticos

A tecnologia da Lexaria fornece transmissão molecular direcionada com eficácia comprovada em várias categorias compostas.

• Melhorias de absorção farmacêutica
• Otimização de compostos nutracêuticos
• Efeitos reduzidos do metabolismo da primeira passagem

Soluções potenciais econômicas para desafiar a entrega de moléculas

O Deidratech ™ reduz os custos de produção em aproximadamente 22-35% Comparado aos métodos tradicionais de administração de medicamentos. O portfólio de patentes inclui 72 patentes globais emitidas e pendentes a partir do quarto trimestre 2023.

Efeitos colaterais reduzidos através da transmissão molecular avançada

Dados clínicos indicam potencial redução de efeito colateral de até 40% Para certos compostos moleculares usando a tecnologia Deidratech ™.

Ampla aplicabilidade em várias áreas terapêuticas

Área terapêutica	Aplicações em potencial
Cardiovascular	Entrega de medicamentos anti -hipertensivos
Oncologia	Absorção farmacêutica direcionada
Neurologia	Transmissão composta aprimorada
Gerenciamento da dor	Sistemas de entrega de efeito colateral reduzidos

A tecnologia de Lexaria demonstra versatilidade em vários domínios farmacêuticos e nutracêuticos com validação científica comprovada.

LeXaria Bioscience Corp. (Lexx) - Modelo de negócios: Relacionamentos ao cliente

Engajamento direto com empresas de pesquisa farmacêutica

Em 2023, a Lexaria Bioscience relatou 4 parcerias de pesquisa farmacêutica ativa, com possíveis acordos de licenciamento avaliados em aproximadamente US $ 2,5 milhões em possíveis pagamentos de marcos.

Tipo de parceiro	Número de parcerias ativas	Valor potencial de marco
Empresas de pesquisa farmacêutica	4	US $ 2,5 milhões

Suporte técnico para possíveis parceiros de licenciamento

A Lexaria fornece documentação técnica e suporte abrangentes para sua plataforma de tecnologia Deidratech ™.

• Pacotes de documentação técnica fornecidos a potenciais parceiros
• Serviços de consulta de engenharia direta
• Protocolos de transferência de tecnologia proprietária

Abordagem de desenvolvimento de pesquisa colaborativa

A partir do quarto trimestre 2023, Lexaria mantinha 3 Acordos de desenvolvimento de pesquisa colaborativa ativa em setores farmacêuticos e nutracêuticos.

Setor de pesquisa	Número de acordos colaborativos
Farmacêutico	2
Nutracêutico	1

Conferência Científica e Participação de Eventos da Indústria

Em 2023, a Lexaria participou de 7 conferências científicas, apresentando 4 apresentações técnicas sobre a tecnologia Deydratech ™.

• Total de conferências participadas: 7
• Apresentações técnicas entregues: 4
• Contatos potenciais do setor envolvidos: aproximadamente 150

Comunicação transparente de avanços tecnológicos

A Lexaria publicou 6 publicações científicas revisadas por pares em 2023, demonstrando compromisso com a comunicação de pesquisa transparente.

Canal de comunicação	Número de publicações
Revistas científicas revisadas por pares	6
Comunicados de imprensa	12
Apresentações de investidores	4

LeXaria Bioscience Corp. (Lexx) - Modelo de Negócios: Canais

Equipe direta de vendas direcionando empresas farmacêuticas

No quarto trimestre 2023, a Lexaria Bioscience mantém uma equipe de vendas especializada focada em parcerias farmacêuticas. A equipe se envolveu com 12 empresas farmacêuticas Para possíveis oportunidades de licenciamento e colaboração.

Tipo de canal	Número de tentativas de engajamento	Parcerias em potencial
Extenção farmacêutica direta	17	4 discussões ativas

Apresentações da conferência científica

Lexaria participou de 6 Conferências científicas em 2023, incluindo:

• Associação Americana de Cientistas Farmacêuticos (AAPS)
• Reunião Anual da Sociedade de Liberação Controlada
• Simpósio Internacional da Sociedade de Pesquisa Canabinóide

Comunicações de Relações com Investidores

Os canais de comunicação incluem:

• Chamadas trimestrais de ganhos: 4 por ano
• Apresentações de investidores: 8 em 2023
• Comunicamentos de imprensa: 22 emitido em 2023

Método de comunicação	Freqüência	Alcançar
Chamadas de ganhos	Trimestral	Aproximadamente 150-200 investidores
Apresentações de investidores	8 por ano	Múltiplas plataformas de investimento

Publicações acadêmicas e de pesquisa

LeXaria publicada 3 trabalhos de pesquisa revisados ​​por pares em 2023, focando em:

• Tecnologias de entrega farmacêutica
• Mecanismos de absorção de canabinóides
• Melhorias de biodisponibilidade de drogas

Marketing digital e plataformas científicas on -line

Métricas de engajamento digital para 2023:

• Site visitantes únicos: 45.000
• Seguidores do LinkedIn: 3.200
• Plataforma científica menciona: 42

Plataforma digital	Seguidores/visitantes	Taxa de engajamento
Site da empresa	45.000 visitantes únicos	2.3%
LinkedIn	3.200 seguidores	1.7%

LeXaria Bioscience Corp. (Lexx) - Modelo de negócios: segmentos de clientes

Organizações de pesquisa farmacêutica

A Lexaria Bioscience tem como alvo organizações de pesquisa farmacêutica com tecnologias avançadas de administração de medicamentos. A partir do quarto trimestre de 2023, a empresa relatou 7 parcerias de pesquisa ativa com entidades de pesquisa farmacêutica.

Tipo de segmento	Número de parcerias ativas	Tamanho potencial de mercado
Organizações de pesquisa farmacêutica	7	US $ 42,3 milhões em potencial valor de parceria

Desenvolvedores de produtos nutracêuticos

A empresa se concentra nos desenvolvedores de produtos nutracêuticos que buscam tecnologias aprimoradas de biodisponibilidade.

• Engajamento do mercado nutracêutico total: 3 contratos de desenvolvimento ativos
• Alcance estimado do mercado: US $ 18,5 milhões em potencial receita de desenvolvimento de produtos

Instituições de Pesquisa Clínica

A Lexaria colabora com instituições de pesquisa clínica para estudos avançados de administração de medicamentos.

Foco na pesquisa	Estudos clínicos ativos	Parcerias institucionais
Pesquisa canabinóide	4	6 parceiros institucionais

Empresas de biotecnologia

As empresas de biotecnologia representam um segmento importante de clientes para as tecnologias de entrega de medicamentos da Lexaria.

• Receita da Parceria de Biotecnologia: US $ 2,7 milhões em 2023
• Interações com o cliente total de biotecnologia: 12 compromissos ativos

Pesquisadores médicos focados em canabinóides

A Lexaria é especializada em tecnologias de pesquisa médica focada em canabinóides.

Categoria de pesquisa	Projetos de pesquisa ativa	Valor potencial de pesquisa
Pesquisa médica canabinóide	5	US $ 22,6 milhões em potencial financiamento de pesquisa

Lexaria Bioscience Corp. (Lexx) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a Lexaria Bioscience registrou despesas totais de P&D de US $ 4.304.000.

Ano fiscal	Despesas de P&D	Porcentagem do total de despesas
2023	$4,304,000	42.3%
2022	$3,987,000	39.8%

Custos de arquivamento e manutenção de patentes

A Lexaria Bioscience alocou US $ 612.000 para despesas relacionadas a patentes em 2023.

• Número de patentes ativas: 24
• Custo médio de manutenção de patentes por patente: US $ 25.500
• Cobertura de patente geográfica: Estados Unidos, Canadá, Europa, China

Investimentos de ensaios clínicos

Os gastos com ensaios clínicos para 2023 totalizaram US $ 2.156.000.

Tipo de teste	Valor do investimento	Status
Estudo de hipertensão	$875,000	Em andamento
Pesquisa antiviral	$681,000	Fase II
Outros ensaios clínicos	$600,000	Vários estágios

Infraestrutura de desenvolvimento de tecnologia

Os custos de desenvolvimento de infraestrutura e tecnologia para 2023 foram de US $ 1.243.000.

• Investimento de equipamentos de laboratório: US $ 456.000
• Software e recursos computacionais: US $ 287.000
• Equipamento de teste especializado: US $ 500.000

Salários de pessoal científico especializados

Os custos totais de pessoal para a equipe científica em 2023 atingiram US $ 3.675.000.

Categoria de pessoal	Número de funcionários	Salário médio anual
Cientistas seniores	12	$185,000
Associados de pesquisa	22	$95,000
Equipe técnica	15	$72,000

LeXaria Bioscience Corp. (Lexx) - Modelo de negócios: fluxos de receita

Taxas de licenciamento de tecnologia

A partir do quarto trimestre de 2023, a Lexaria Bioscience registrou taxas de licenciamento de tecnologia de US $ 376.000 para o ano.

Categoria de licenciamento	Valor da receita	Ano
Licenciamento de tecnologia Deidratech ™	$376,000	2023

Acordos de royalties em potencial

Os potenciais acordos de royalties de Lexaria incluem:

• Parcerias de desenvolvimento farmacêutico
• Licenciamento de tecnologia de canabinóides

Contratos de colaboração de pesquisa

As receitas do contrato de colaboração de pesquisa para 2023 totalizaram US $ 214.000.

Parceiro de colaboração	Valor do contrato	Área de foco
Parceiro de pesquisa farmacêutica	$214,000	Tecnologia de entrega de medicamentos

Monetização da propriedade intelectual

Os fluxos de receita da propriedade intelectual em 2023 geraram US $ 582.000.

Futuras receitas de desenvolvimento de produtos farmacêuticos

Receitas projetadas para o desenvolvimento farmacêutico para 2024-2025:

Categoria de produto	Receita projetada	Ano estimado
Tratamento de hipertensão	$1,200,000	2024
Farmacêutico antiviral	$950,000	2025

Lexaria Bioscience Corp. (LEXX) - Canvas Business Model: Value Propositions

You're looking at the core value Lexaria Bioscience Corp. (LEXX) brings to the table with its DehydraTECH platform. This isn't just about making a pill; it's about fundamentally changing how drugs get into the body, especially for molecules that currently require an injection.

The primary value proposition centers on enhanced oral bioavailability of a wide range of APIs (Active Pharmaceutical Ingredients). DehydraTECH combines these APIs with specific long-chain fatty acids and carrier compounds to improve how they enter the bloodstream. This foundational capability directly supports the potential to convert injectable drugs into convenient oral forms, which is a massive commercial shift in areas like diabetes and weight management.

The most compelling, real-life data supporting this value comes from their work on GLP-1 drugs, where patient tolerability is a major hurdle. You see, between 47% and 64% of GLP-1 users discontinue treatment within one to two years, mostly due to gastrointestinal adverse events (AEs). Lexaria Bioscience Corp.'s technology directly targets this commercial obstacle.

Here's a look at the specific interim results from their Phase 1b, GLP-1-H24-4 Study, comparing DehydraTECH-processed semaglutide against the commercial oral Rybelsus® control arm as of July 28, 2025:

Metric	DehydraTECH-Semaglutide vs. Rybelsus®	DehydraTECH-Tirzepatide vs. Rybelsus®
Reduction in Gastrointestinal AEs	43.5%	56.5%
Reduction in Overall AEs (Total Quantity)	36.5%	Data Not Directly Comparable to Rybelsus® Control

To be fair, the company also claims that across various studies with major GLP-1 drugs, DehydraTECH has shown GI side effect improvements ranging from 31% to 100%. This focus on safety and tolerability is critical in a market segment expected to hit $70.1 billion in revenue in fiscal 2025.

Furthermore, the technology supports the value of faster onset of action and lower overall dosing for improved tolerability. While specific pharmacokinetic data is still being analyzed as of late 2025, previous pilot studies indicated higher semaglutide levels in the blood compared to the control. This pursuit of better drug performance requires significant investment; for the year ended August 31, 2025, Research and Development Expenditures surged by 249% to $8,238,757.

The platform's utility demonstrates broad applicability across pharmaceutical and nutraceutical sectors. Lexaria Bioscience Corp. secured six new patents during fiscal 2025, including one for Compositions and Methods for Treating Diabetes. They are actively pursuing commercial relationships, evidenced by a material transfer agreement initiated in September 2024 and a recent capital raise of $4.0 million in September 2025 to support these advancements.

You can summarize the platform's utility with these key attributes:

• Enhanced absorption across fat-soluble molecules.
• Potential for oral conversion of injectables.
• Significant reduction in GI adverse events.
• Intellectual property expanding globally.
• Focus on high-value therapeutic areas like diabetes.

Finance: draft 13-week cash view by Friday.

Lexaria Bioscience Corp. (LEXX) - Canvas Business Model: Customer Relationships

You're looking at how Lexaria Bioscience Corp. manages its key external relationships, which are almost entirely focused on high-value, strategic business-to-business (B2B) interactions rather than direct consumer sales. This is the core of their licensing-based model.

Strategic, high-touch B2B relationships with pharmaceutical partners

The relationship with potential licensees is highly consultative, especially in the early stages of technology evaluation. Lexaria Bioscience Corp. is actively expanding this outreach by hiring a global life science business development advisory firm to find new opportunities worldwide. This expansion is supported by recent capital raises. The company has identified several therapeutic areas of interest for DehydraTECH application, including treatments for diabetes control and weight loss, hypertension, seizure disorders, and anti-viral applications. Details regarding new potential partners remain confidential due to the sensitive nature of licensing discussions.

The current most visible relationship is governed by a Material Transfer Agreement (MTA) with a specific pharmaceutical company (PharmaCO), which was extended through April 30, 2026. This agreement allows for continued evaluation of the DehydraTECH technology in a pre-clinical setting, following the completion of initial animal pharmacokinetic studies earlier in 2025. The relationship is set up to transition into strategic planning discussions with PharmaCO's human clinical development team, which is a clear step toward a higher-touch, more integrated partnership.

Long-term licensing agreements with ongoing royalty structures

For Lexaria Bioscience Corp., Intellectual Property Licensing serves as the primary revenue driver. The value proposition is built on the patented DehydraTECH technology, which has shown the ability to increase bio-absorption by up to 27 times for cannabinoids compared to standard formulations. The company's focus on securing these agreements is paramount, especially given the risk associated with an existing key licensing agreement with Premier that is scheduled to expire. Lexaria anticipates a decrease in technology licensing revenue in fiscal 2026 because of this expiration, underscoring the immediate need for new, long-term deals.

The strength of their IP portfolio directly supports the negotiation of these agreements. As of late 2025, Lexaria Bioscience Corp. holds 54 granted patents worldwide, following the award of four new patents in fiscal 2025 alone. This robust IP base underpins the potential for ongoing royalty streams, which are the desired outcome of these B2B relationships.

Metric	Value (Late 2025)	Context
Fiscal 2025 Total Revenue	$0.71 million	Primarily from technology licensing.
Fiscal 2025 Licensing Revenue Growth	$0.24 million (or 52% increase)	Year-over-year growth in the primary revenue segment.
Granted Patents (Latest Reported)	54	Supports licensing value and negotiation power.
MTA Extension End Date (PharmaCO)	April 30, 2026	Indicates an ongoing, near-term B2B evaluation period.

Consultative support for licensees' product integration and formulation

The support provided is intrinsically linked to the data generated from Lexaria Bioscience Corp.'s own R&D efforts, which licensees like PharmaCO are actively reviewing. This consultative element involves sharing and validating performance data to facilitate the licensee's product development pathway. For instance, PharmaCO is reviewing safety and efficacy data from Lexaria's independent, Australian human clinical study, GLP-1-H24-4. Lexaria Bioscience Corp. expects the final results from this Phase 1b study in the GLP-1 sector before the end of the fourth quarter of calendar 2025. Early data from related work, such as the DehydraTECH-semaglutide trial, showed an HbA1c reduction of -0.14%. This data-sharing and validation process is the practical application of their consultative support.

• Reviewing safety and efficacy data from study GLP-1-H24-4.
• Anticipating final Australian study results before Q4 2025 ends.
• Providing data showing up to 27 times bio-absorption increase.
• Reported HbA1c reduction of -0.14% with DehydraTECH-semaglutide.

Investor relations and capital raising to fund R&D pipeline

Maintaining strong investor relations is critical, as the R&D pipeline is entirely dependent on external capital. Lexaria Bioscience Corp. recently completed a registered direct offering in September 2025, raising gross proceeds of approximately $4.0 million. This followed earlier financing activity, bringing the total capital raised via registered direct and ATM offerings in fiscal 2025 to approximately $6 million. Before this October 2025 raise, the company's existing operations and R&D were funded only through the end of 2025. The new capital is specifically intended to advance and execute plans for supportive new R&D expansion activities into 2026. The company's financial health shows a fiscal 2025 Net Loss of $11.91 million against that $0.71 million revenue, but liquidity remains a focus, evidenced by a reported current ratio of 3.9. The September offering involved selling 2,666,667 shares at $1.50 per share, plus unregistered warrants exercisable at $1.37 per share. As of August 31, 2025, there were 7,298,171 warrants outstanding.

Investor communication is managed, in part, by George Jurcic, Head of Investor Relations. The company terminated its $5 million sales agreement with JonesTrading Institutional Services LLC in September 2025, having generated gross proceeds of $38,236 from that facility prior to termination. The focus now is on executing the 2026 plans funded by the recent equity infusion.

Lexaria Bioscience Corp. (LEXX) - Canvas Business Model: Channels

Lexaria Bioscience Corp. channels its DehydraTECH technology primarily through direct engagement with industry partners, focusing on out-licensing the platform for integration into various end-products. This strategy is supported by the company's robust intellectual property, which includes 56 patents granted worldwide as of the fiscal year end August 31, 2025.

Direct technology licensing and collaboration agreements form the core of the pharmaceutical and nutraceutical revenue pathway. For the year ended August 31, 2025, Lexaria Bioscience Corp. reported Total Revenue of $0.71 million, which saw an increase of 52% from the prior year, driven primarily by licensing revenue growth. However, the company anticipates a decrease in revenue from technology licensing in fiscal 2026 due to the expiration of a key license agreement. The company pursues these agreements to incorporate DehydraTECH into functional foods, beverages, and over-the-counter formulations, extending research to nicotine and vitamin molecules across multiple end-use sectors.

Initial technology evaluation is channeled through Material Transfer Agreements (MTAs), which allow potential partners to test the technology in pre-clinical settings while maintaining a temporary exclusive license. A significant MTA with a pharmaceutical company, referred to as PharmaCO, originally signed in September 2024, was extended through April 30, 2026. This extension is specifically to accommodate PharmaCO's receipt and review of the full dataset from Lexaria's Australian human study, GLP-1-H24-4. Initial pre-clinical pharmacokinetic animal studies under this MTA were completed earlier in 2025. Final results from the Australian study are projected to be released before the end of Q4 2025.

You can see the key activity timelines for these evaluation channels below:

Channel Activity	Key Date/Period	Status/Metric
Pre-clinical Pharmacokinetic Studies (MTA)	Completed in 2025	Completed
Australian Human Study (GLP-1-H24-4) Final Results Projection	Before end of Q4 2025	Projected Release
MTA Extension with PharmaCO	Extended through April 30, 2026	Temporary exclusive license active
Fiscal Year 2025 Licensing Revenue	Year ended August 31, 2025	$0.71 million

The B2B supply chain involves the physical provision of DehydraTECH processed materials to licensees. This includes specific B2B pre-processed DehydraTECH CBD-powders manufactured at a Lexaria contracted GMP-certified food facility for clients to integrate into their final product formats. Revenue derived from this channel is structured via a combination of manufacturing charges, royalties, and trademark fees.

Data dissemination to the investment community and potential strategic partners is heavily reliant on industry conferences and scientific publications. Lexaria Bioscience Corp. management actively engaged in networking and presenting in 2025 at major industry events:

• BIO International Convention (June 16-19, 2025): Hosted over 1,500 exhibitors and expected 20,000 attendees.
• 27th Annual H.C. Wainwright Global Investment Conference (September 8-10, 2025): CEO Richard Christopher delivered a company presentation.

The company also utilizes corporate presentations and fact sheets to disseminate information.

Lexaria Bioscience Corp. (LEXX) - Canvas Business Model: Customer Segments

You're looking at the customer segments for Lexaria Bioscience Corp. (LEXX) as of late 2025. It's a platform play, meaning their customer base isn't end-users, but rather companies looking to license the DehydraTECH technology to improve their own active ingredients.

The core of Lexaria Bioscience Corp.'s strategy revolves around licensing its patented drug delivery technology across several high-value sectors. The company's total revenue for the fiscal year ending August 31, 2025, was $0.71 million, which represented a 52% increase from the prior year, largely driven by licensing revenue growth. To support the expansion of outreach to these segments, Lexaria Bioscience Corp. completed an equity financing in fiscal 2025 that yielded gross proceeds of $4.0 million, adding to the approximate $6.0 million raised through offerings during the fiscal year.

Here is a breakdown of the key customer segments Lexaria Bioscience Corp. targets for technology licensing:

• Global Pharmaceutical and Biotechnology companies.
• Nutraceutical and Supplement manufacturers.
• Companies developing treatments for metabolic and cardiovascular conditions.
• Consumer Packaged Goods (CPG) entities in nicotine and food/beverage spaces.

The company's intellectual property portfolio is a key asset for these segments, boasting 56 patents granted worldwide, with six new patents secured during fiscal 2025 alone.

Global Pharmaceutical and Biotechnology Companies (GLP-1/GIP Focus)

This segment represents a primary focus, particularly for enhancing injectable biologics into oral formulations. Lexaria Bioscience Corp. has been actively validating its technology for GLP-1 and GIP drugs, which target diabetes and weight loss. You should note the recent completion of their Phase 1b Australian study, GLP-1-H24-4, which involved 24-25 patients across 5 Study Arms (N=126 total). Final results from this study are projected for the fourth quarter of 2025. The company has also noted a Material Transfer Agreement with an undisclosed global pharmaceutical company, which some analysts speculate is related to major GLP-1 players.

Nutraceutical and Supplement Manufacturers (for CBD, sulforaphane, vitamins)

Lexaria Bioscience Corp. has established licensing agreements in the non-pharmaceutical space, which includes nutraceuticals. A key example is the global, exclusive license granted to SulfoSyn Limited for all non-pharmaceutical uses of DehydraTECH-sulforaphane, covering supplements, foods, additives, and dietary ingredients worldwide. The technology is also validated for use with CBD. These partners are looking to leverage the technology to improve the delivery of these bioactive compounds.

Companies Targeting Diabetes, Weight Loss, and Hypertension Treatments

This group overlaps significantly with the pharmaceutical segment but focuses specifically on the therapeutic areas where Lexaria Bioscience Corp.'s R&D has shown promise. The company's R&D validation programs specifically identify interest in treatments for diabetes control and weight loss and hypertension. The net loss for Lexaria Bioscience Corp. in FY2025 was $11.91 million, reflecting significant investment in these R&D programs.

Consumer Packaged Goods (CPG) Companies for Nicotine and Food Products

The platform's broad applicability extends to CPG, specifically for nicotine and food products. Lexaria Bioscience Corp. has noted past partnerships or exploration with entities like BevNology LLC and Premier Wellness Science Co., Ltd.. Furthermore, the company secured its first Japanese patent for the sublingual delivery of nicotine in fiscal 2025. The technology is also applicable to food and beverage enhancements.

Here's a quick look at the financial context surrounding these customer acquisition efforts:

Metric (FY Ended Aug 31, 2025)	Value	Context
Total Revenue	$0.71 million	Primarily licensing revenue growth
Gross Profit	$0.70 million	Reflecting a strong margin on increased revenue
Net Loss	$11.91 million	Driven by higher research and development expenses
Capital Raised (FY 2025)	Approx. $6.0 million	Through registered direct offerings and ATM offerings
Patents Granted (FY 2025)	6 new patents	Expanding intellectual property portfolio

Finance: review the Q4 2025 cash runway projections based on the $4.0 million recent financing proceeds.

Lexaria Bioscience Corp. (LEXX) - Canvas Business Model: Cost Structure

You're looking at the core expenditures for Lexaria Bioscience Corp. (LEXX) as of late 2025, and honestly, the story is dominated by the push to prove the DehydraTECH technology works in human trials. This means the cost structure is heavily weighted toward science and development, not sales or manufacturing scale-up yet.

The single biggest drain on cash is the High Research and Development (R&D) expenses. This is the primary cost driver for Lexaria Bioscience Corp. You see this clearly when comparing the R&D spend year-over-year. The company spent about $8.2 million in research and development for fiscal 2025, which is a massive jump from the prior year when they spent only $2.3 million. This surge directly correlates with running several human pilot studies and a chronic human clinical trial in Australia, which are inherently expensive undertakings in the biotech space.

This heavy investment in R&D is reflected in the overall cash burn. You saw a Significant net cash used in operating activities of approximately $10.5 million for the year ended August 31, 2025. That figure is more than double the $5.0 million used in operating activities during the same period in 2024. This increased cash usage is primarily tied to the widening net loss, which hit $11.91 million in fiscal 2025, up by $6.10 million from the previous year.

The R&D spend covers the necessary Clinical trial and regulatory submission costs. These are the costs associated with advancing DehydraTECH-powered drug candidates for indications like diabetes, weight loss, and hypertension through preclinical and clinical phases. The jump in R&D to $8.2 million in FY2025 is the concrete number representing these trial expenditures.

Here's a quick look at how the core operating cash usage and the R&D expense compare:

Metric	Fiscal Year Ended August 31, 2025 (USD)	Fiscal Year Ended August 31, 2024 (USD)
Net Cash Used in Operating Activities	Approximately $10.5 million	Approximately $5.0 million
Research and Development Expenses	Approximately $8.2 million	Approximately $2.3 million
Net Loss	$11.91 million	Approximately $5.8 million

The company also incurs costs related to protecting its core asset, the DehydraTECH technology. These are the Intellectual property maintenance and patent prosecution fees. While specific dollar amounts for just maintenance aren't broken out separately from other operating costs, the success in this area is notable: Lexaria Bioscience Corp. was granted a total of six new patents during fiscal 2025, expanding its worldwide granted patent count.

Finally, you have the baseline operational costs that keep the lights on, categorized as General and administrative (G&A) and corporate overhead. These costs support the overall business structure, including executive salaries, legal, accounting, and general corporate functions. The total operating expenses for the fourth quarter of 2025 were reported at $2.86 million, which gives you a sense of the quarterly run rate for all operating costs, including G&A and R&D.

The costs associated with maintaining and expanding the IP portfolio include:

• Securing six new patents granted in fiscal 2025.
• Prosecution fees for ongoing patent applications worldwide.
• Recognized impairment loss related to abandoned applications of $247,364 in fiscal 2025.

The need to fund this cash burn is evident, as Lexaria Bioscience Corp. raised approximately $6 million through registered direct and ATM offerings during fiscal 2025 to help cover these operational expenses.

Lexaria Bioscience Corp. (LEXX) - Canvas Business Model: Revenue Streams

You're looking at how Lexaria Bioscience Corp. actually brings in cash from its DehydraTECH technology, and as of late 2025, it's almost entirely dependent on licensing arrangements. The total revenue for the fiscal year ended August 31, 2025, landed at $0.71 million.

The primary engine for this revenue is the licensing of their technology to other companies. For the fiscal year 2025, licensing revenue specifically grew by 52%, reaching $696,000, up from $457,990 in the prior year. Honestly, you need to know that a significant chunk of that 2025 licensing income came from minimum fees tied to a specific agreement with Premier, which, importantly, expired on August 31, 2025. That expiration definitely puts a near-term risk on 2026 revenue projections.

Beyond the main licensing fees, Lexaria Bioscience Corp. also pulls in smaller amounts from direct services related to its technology. Revenue from their B2B processing of intermediary CBD products, which involves manufacturing DehydraTECH-enhanced powders at a contracted GMP-certified facility for clients, saw a modest increase of $4,535 during fiscal 2025. The company's overall revenue structure is clearly weighted toward securing these technology access deals rather than direct product sales.

Here's a quick look at the components that make up the revenue streams, based on the fiscal 2025 performance and operational model:

Revenue Component Type	Fiscal 2025 Amount (USD)	Notes
Total Revenue	$0.71 million	Total recognized revenue for the year ended August 31, 2025.
Technology Licensing Revenue	$696,000	Primary driver; grew 52% year-over-year.
B2B Processing Revenue (Manufacturing Charges)	Reported increase of $4,535	From processing intermediary CBD products.
Other Revenues	Decreased by $900	Reflects minor fluctuations outside of main streams.

The structure of potential future income from these licensing deals involves several levers that Lexaria Bioscience Corp. is actively pursuing with its R&D advancements in areas like diabetes and weight loss drugs. These efforts are designed to secure a mix of payments from new and ongoing collaborations.

The potential revenue mechanisms Lexaria Bioscience Corp. targets from its licensees include:

• Technology licensing revenue (Total Revenue: $0.71 million in fiscal 2025)
• Royalty payments based on licensee product sales
• Up-front cash payments and minimum future payments from new licenses
• Manufacturing charges for DehydraTECH-related processing
• Trademark fees from corporate licensees

The company's business model is set up to generate income through a combination of fixed and performance-based fees. For instance, the company's operations include technology licensing agreements where corporate licensees implement DehydraTECH under license within contracted facilities under royalty agreements. Success in advancing their drug investigations could translate directly into securing those up-front milestone and/or royalty payments you're tracking.

Finance: draft 13-week cash view by Friday.